Categories: News

Apollo Endosurgery, Inc. to Report First Quarter Results on May 2, 2019

AUSTIN, Texas–(BUSINESS WIRE)–Apollo Endosurgery, Inc. (“Apollo”) (Nasdaq:APEN), a global leader in
less invasive medical devices for gastrointestinal and bariatric
procedures, today announced that the Company is scheduled to release its
financial results for the first quarter ended March 31, 2019 on
Thursday, May 2, 2019, after the U.S. stock markets close.

Apollo will hold a conference call on Thursday, May 2, 2019 at 3:30 p.m.
CT / 4:30 p.m. ET to discuss the results. The dial-in numbers are (866)
393-4306 for domestic callers and (734) 385-2616 for international
callers. The conference ID number is 7094276. A live webcast of the
conference call will be available online from the investor relations
page of the Company’s corporate website at www.apolloendo.com.

A replay of the webcast will be made available on Apollo’s website, www.apolloendo.com,
shortly after completion of the call.

About Apollo Endosurgery, Inc.

Apollo Endosurgery, Inc. is a medical technology company focused on less
invasive therapies to treat various gastrointestinal conditions, ranging
from gastrointestinal defect repairs to the interventional treatment of
obesity. Apollo’s device-based therapies are an alternative to invasive
surgical procedures, thus lowering complication rates and reducing total
healthcare costs. Apollo’s products are offered in over 70 countries
today and include the OverStitch™ Endoscopic Suturing System, the
OverStitch Sx™ Endoscopic Suturing System, and the ORBERA® Intragastric
Balloon.

Apollo’s common stock is traded on Nasdaq Global Market under the symbol
“APEN”. For more information regarding Apollo Endosurgery, go to: www.apolloendo.com.

Contacts

Apollo Endosurgery, Inc.
John Gillings, 512-279-5100
Investor
Relations
investor-relations@apolloendo.com

Staff

Recent Posts

FendX Announces Fifth Real-World Testing Site for REPELWRAP(TM) Film with New Vista Society, a Long-Term Care and Senior Housing Provider

Testing nanotechnology to assess for further optimization of manufacturing process at DunmoreOakville, Ontario--(Newsfile Corp. -…

1 hour ago

Alzheon Raises $100 Million Series E Financing Round to Advance Development and Commercialization of Oral Tablet ALZ-801/Valiltramiprosate for Treatment of Alzheimer’s Disease

Proceeds Will Support Completion of Pivotal APOLLOE4 Phase 3 Study Evaluating ALZ-801/Valiltramiprosate and Regulatory Filings…

2 hours ago

Twenty Percent Of The World’s Employees Experience Loneliness While Global Employee Engagement Stagnated And Employee Wellbeing Declined

WASHINGTON, June 12, 2024 /PRNewswire/ -- Gallup's latest State of the Global Workplace report finds that…

2 hours ago

Alida Biosciences Announces Series A Funding and Early Access Launch of Innovative Products for Epitranscriptomic Research

SAN DIEGO, June 12, 2024 /PRNewswire/ -- Alida Biosciences (AlidaBio), an innovator in epigenomic research tools,…

2 hours ago

ScandiNova joins the United Nations Global Compact

UPPSALA, Sweden, June 12, 2024 /PRNewswire/ -- ScandiNova Group is proud to announce its participation…

2 hours ago